Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This phase III trial studies how well lenalidomide in combination with ixazomib works
compared to lenalidomide alone in treating patients with evidence of residual multiple
myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of
multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better
than giving lenalidomide alone in treating patients with evidence of residual multiple
myeloma after a stem cell transplantation.